Disease Modification in Rheumatoid Arthritis - Competition for the anti-TNF failure

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-04-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF’s is reaching a maximum and competition moves to anti-TNF failure patients.


Scope

  • Detailed pipeline analysis for key products in a specific rheumatoid arthritis indication, plus drug sales forecasts to 2016
  • Overview of patient potential, segmentation by indication and unmet needs in rheumatoid arthritis across the seven major markets
  • Benchmarking of key clinical and company attractiveness of the late-phase pipeline products
  • Comprehensive and up-to-date clinical trial information


    • Report Highlights
    The anti-TNF failure segment will be an area of increased competition over the next five years, as new products avoid direct confrontation with the established anti-TNF's. This population will increase as more patients use biologics and cycle through the anti-TNF's, but there are a finite number of eligible patients, especially if prices remain high.

    The race is on between the Roche/Genentech/Biogen Idec and the Genmab/GSK partnerships to launch a CD20-inhibiting monoclonal antibody to follow, and build upon, the success shown by Rituxan/MabThera (rituximab) in the RA indication. At present Roche with ocrelizumab have a slight, but uncertain, advantage.

    The majority (58%) of projects in human clinical trials are in Phase II development showing the positive growth potential in the RA disease area. However, a large proportion are small molecule, orally available products, which have in the past shown a high attrition rate in Phase II.


    Reasons to Purchase

  • Understand why pricing restraint is necessary for the continued exponential uptake and commercial growth of the biologic DMARDs
  • Quantify the future size and potential of the market for novel treatments in the rheumatoid arthritis indication
  • Use analysis of the common molecular targets under investigation to find gaps in the market for your product

    • Table of Contents

    Other users found this report page using the following search terms: rheumatoid arthritis autoimmune arthritis rheumatoid phase action actemra ocrelizumab antitnf cimziamechanism unmet cp690 550

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.